Monografie
Older age onset of systemic sclerosis - accelerated disease progression in all disease subsets
- Sprache
-
Englisch
- Identifier
-
1221959670
Beteiligte Personen und Organisationen
Moinzadeh, Pia
Kuhr, Kathrin
Siegert, Elise
Müller-Ladner, Ulf
Riemekasten, Gabriela
Günther, Claudia
Kötter, Ina
Henes, Jörg Christoph
Blank, Norbert
Zeidler, Gabriele
Pfeiffer, Christiane
Juche, Aaron
Jandova, Ilona
Ehrchen, Jan
Schmalzing, Marc
Susok, Laura
Schmeiser, Tim
Sunderkötter, Cord
Distler, Jörg Hans Wilhelm
Worm, Margitta
Kreuter, Alexander
Krieg, Thomas
Hunzelmann, Nicolas
Kuhr, Kathrin
Siegert, Elise
Müller-Ladner, Ulf
Riemekasten, Gabriela
Günther, Claudia
Kötter, Ina
Henes, Jörg Christoph
Blank, Norbert
Zeidler, Gabriele
Pfeiffer, Christiane
Juche, Aaron
Jandova, Ilona
Ehrchen, Jan
Schmalzing, Marc
Susok, Laura
Schmeiser, Tim
Sunderkötter, Cord
Distler, Jörg Hans Wilhelm
Worm, Margitta
Kreuter, Alexander
Krieg, Thomas
Hunzelmann, Nicolas
- DOI
-
10.1093/rheumatology/keaa127
- URN
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
26.01.2023, 13:53 MEZ
Objekttyp
- Monografie
Beteiligte
- Moinzadeh, Pia
- Kuhr, Kathrin
- Siegert, Elise
- Müller-Ladner, Ulf
- Riemekasten, Gabriela
- Günther, Claudia
- Kötter, Ina
- Henes, Jörg Christoph
- Blank, Norbert
- Zeidler, Gabriele
- Pfeiffer, Christiane
- Juche, Aaron
- Jandova, Ilona
- Ehrchen, Jan
- Schmalzing, Marc
- Susok, Laura
- Schmeiser, Tim
- Sunderkötter, Cord
- Distler, Jörg Hans Wilhelm
- Worm, Margitta
- Kreuter, Alexander
- Krieg, Thomas
- Hunzelmann, Nicolas
Ähnliche Objekte (12)
Versorgungsrealität der stationären vasoaktiven Therapie mit Prostazyklinderivaten bei Patienten mit akralen Durchblutungsstörungen bei systemischer Sklerose in Deutschland = Reality of inpatient vasoactive treatment with prostacyclin derivatives in patients with acral circulation disorders due to systemic sclerosis in Germany
Disease progression in systemic sclerosis-overlap syndrome is significantly different from limited and diffuse cutaneous systemic sclerosis
Autologous hematopoietic stem cell transplantation improves long-term survival - data from a national registry
Anti-acid therapy in SSc-associated interstitial lung disease: long-term outcomes from the German Network for Systemic Sclerosis
S2k guideline: Diagnosis and management of cutaneous lupus erythematosus – Part 2: Therapy, risk factors and other special topics
S2k guideline: Diagnosis and management of cutaneous lupus erythematosus – Part 2: Therapy, risk factors and other special topics
S2k guideline: Diagnosis and management of cutaneous lupus erythematosus – Part 1: Classification, diagnosis, prevention, activity scores
S2k guideline: Diagnosis and management of cutaneous lupus erythematosus - Part 1: Classification, diagnosis, prevention, activity scores
Inhibition of casein kinase II reduces TGFβ induced fibroblast activation and ameliorates experimental fibrosis
Incidence and predictors of cutaneous manifestations during the early course of systemic sclerosis: a 10-year longitudinal study from the EUSTAR database
Incidences and Risk Factors of Organ Manifestations in the Early Course of Systemic Sclerosis: A Longitudinal EUSTAR Study
Impact of systemic Sclerosis-associated interstitial lung disease with and without pulmonary hypertension on survival : : a large cohort study of the German network for systemic Sclerosis
Versorgungsrealität der stationären vasoaktiven Therapie mit Prostazyklinderivaten bei Patienten mit akralen Durchblutungsstörungen bei systemischer Sklerose in Deutschland = Reality of inpatient vasoactive treatment with prostacyclin derivatives in patients with acral circulation disorders due to systemic sclerosis in Germany
Disease progression in systemic sclerosis-overlap syndrome is significantly different from limited and diffuse cutaneous systemic sclerosis
Autologous hematopoietic stem cell transplantation improves long-term survival - data from a national registry
Anti-acid therapy in SSc-associated interstitial lung disease: long-term outcomes from the German Network for Systemic Sclerosis
S2k guideline: Diagnosis and management of cutaneous lupus erythematosus – Part 2: Therapy, risk factors and other special topics
S2k guideline: Diagnosis and management of cutaneous lupus erythematosus – Part 2: Therapy, risk factors and other special topics
S2k guideline: Diagnosis and management of cutaneous lupus erythematosus – Part 1: Classification, diagnosis, prevention, activity scores
S2k guideline: Diagnosis and management of cutaneous lupus erythematosus - Part 1: Classification, diagnosis, prevention, activity scores
Inhibition of casein kinase II reduces TGFβ induced fibroblast activation and ameliorates experimental fibrosis
Incidence and predictors of cutaneous manifestations during the early course of systemic sclerosis: a 10-year longitudinal study from the EUSTAR database
Incidences and Risk Factors of Organ Manifestations in the Early Course of Systemic Sclerosis: A Longitudinal EUSTAR Study
Impact of systemic Sclerosis-associated interstitial lung disease with and without pulmonary hypertension on survival : : a large cohort study of the German network for systemic Sclerosis
Versorgungsrealität der stationären vasoaktiven Therapie mit Prostazyklinderivaten bei Patienten mit akralen Durchblutungsstörungen bei systemischer Sklerose in Deutschland = Reality of inpatient vasoactive treatment with prostacyclin derivatives in patients with acral circulation disorders due to systemic sclerosis in Germany
Disease progression in systemic sclerosis-overlap syndrome is significantly different from limited and diffuse cutaneous systemic sclerosis
Autologous hematopoietic stem cell transplantation improves long-term survival - data from a national registry
Anti-acid therapy in SSc-associated interstitial lung disease: long-term outcomes from the German Network for Systemic Sclerosis
S2k guideline: Diagnosis and management of cutaneous lupus erythematosus – Part 2: Therapy, risk factors and other special topics
S2k guideline: Diagnosis and management of cutaneous lupus erythematosus – Part 2: Therapy, risk factors and other special topics
S2k guideline: Diagnosis and management of cutaneous lupus erythematosus – Part 1: Classification, diagnosis, prevention, activity scores
S2k guideline: Diagnosis and management of cutaneous lupus erythematosus - Part 1: Classification, diagnosis, prevention, activity scores
Inhibition of casein kinase II reduces TGFβ induced fibroblast activation and ameliorates experimental fibrosis
Incidence and predictors of cutaneous manifestations during the early course of systemic sclerosis: a 10-year longitudinal study from the EUSTAR database
Incidences and Risk Factors of Organ Manifestations in the Early Course of Systemic Sclerosis: A Longitudinal EUSTAR Study